FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

210 results

abraxane
(Paclitaxel)
Abraxis BioScience, LLC
Usage: ABRAXANE is indicated for treating metastatic breast cancer after chemotherapy failure, as well as for first-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with carboplatin. It is also indicated for first-line treatment of metastatic pancreatic adenocarcinoma combined with gemcitabine.
actimmune
(Interferon gamma-1b)
Horizon Therapeutics USA, Inc.
Usage: ACTIMMUNE is indicated for reducing serious infections in patients with Chronic Granulomatous Disease (CGD) and for delaying disease progression in severe, malignant osteopetrosis (SMO).
adcetris
(brentuximab vedotin)
SEAGEN INC.
Usage: ADCETRIS is indicated for treating adult and pediatric patients with previously untreated or relapsed classical Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL), as well as for consolidation post-transplant in high-risk cHL. It is used in combination with specific chemotherapy regimens.
adstiladrin
(nadofaragene firadenovec-vncg)
Ferring Pharmaceuticals
Usage: ADSTILADRIN® is indicated for treating high-risk BCG-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) in adults, specifically for those with carcinoma in situ (CIS) with or without papillary tumors.
afinitor - everolimus tablet
(Everolimus)
Novartis Pharmaceuticals Corporation
akynzeo
(Netupitant and Palonosetron)
Helsinn Therapeutics (U.S.), Inc.
Usage: AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing initial and repeat courses of highly emetogenic cancer chemotherapy, used in combination with dexamethasone. It consists of palonosetron and netupitant (or fosnetupitant in injectable form).
alecensa
(ALECTINIB HYDROCHLORIDE)
Genentech, Inc.
Usage: ALECENSA is indicated for the adjuvant treatment of adults with resected ALK-positive non-small cell lung cancer (NSCLC), and for the treatment of adult patients with metastatic ALK-positive NSCLC, both as detected by an FDA-approved test.
alunbrig
(brigatinib)
Takeda Pharmaceuticals America, Inc.
Usage: ALUNBRIG is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), confirmed by an FDA-approved test.
aphexda
(Motixafortide)
BioLineRx USA Inc
Usage: APHEXDA is indicated, in combination with filgrastim (G-CSF), for mobilizing hematopoietic stem cells into peripheral blood for collection and autologous transplantation in patients with multiple myeloma.
arimidex
(Anastrozole)
ANI Pharmaceuticals, Inc.
Usage: ARIMIDEX is indicated for adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for first-line and second-line treatment of hormone receptor-positive or unknown locally advanced and metastatic breast cancer, particularly after disease progression on tamoxifen therapy.

Oncology drugs

abraxane

actimmune

adcetris

adstiladrin

afinitor - everolimus tablet

akynzeo

alecensa

alunbrig

aphexda

arimidex